• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

迈向癌症的反义寡核苷酸疗法：处于临床开发阶段的ISIS化合物

Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.

作者信息

Holmlund J T, Monia B P, Kwoh T J, Dorr F A

机构信息

ISIS Pharmaceuticals Inc, Carlsbad, CA 92008, USA.

出版信息

Curr Opin Mol Ther. 1999 Jun;1(3):372-85.

PMID:11713802
Abstract

Antisense oligonucleotides offer the promise of therapeutic effect with few toxic effects, by virtue of their high selectivity. Preclinical studies have provided evidence of antisense effects in vitro and in vivo, and phase I clinical trials have demonstrated safety, feasibility and activity of antisense oligonucleotides for the treatment of cancer. This review summarizes the status of development of three anticancer antisense oligonucleotides from ISIS Pharmaceuticals.

摘要

反义寡核苷酸凭借其高选择性，有望产生治疗效果且副作用极少。临床前研究已提供了体外和体内反义效应的证据，并且I期临床试验已证明反义寡核苷酸用于癌症治疗的安全性、可行性和有效性。本综述总结了ISIS制药公司三种抗癌反义寡核苷酸的研发状况。

相似文献

1
Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.迈向癌症的反义寡核苷酸疗法：处于临床开发阶段的ISIS化合物
Curr Opin Mol Ther. 1999 Jun;1(3):372-85.
2
Technology evaluation: ISIS-3521.技术评估：ISIS - 3521
Curr Opin Mol Ther. 1999 Jun;1(3):393-8.
3
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.ISIS 5132（一种c-raf-1反义寡核苷酸抑制剂）对晚期癌症患者进行每周24小时静脉输注的I期试验。
Clin Cancer Res. 2001 May;7(5):1214-20.
4
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.一项针对激素难治性前列腺癌患者的反义寡核苷酸ISIS 3521和ISIS 5132的随机II期及药代动力学研究。
Clin Cancer Res. 2002 Aug;8(8):2530-5.
5
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.ISIS 3521与ISIS 5132用于局部晚期或转移性结直肠癌患者的II期随机研究：加拿大国家癌症研究所临床试验组研究
Clin Cancer Res. 2002 Jul;8(7):2188-92.
6
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.蛋白激酶C-α反义寡核苷酸ISIS 3521联合5-氟尿嘧啶和亚叶酸钙用于晚期癌症患者的I期临床及药代动力学研究。
Clin Cancer Res. 2002 Apr;8(4):1042-8.
7
Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.蛋白激酶C-α表达的反义寡核苷酸抑制剂对裸鼠人肿瘤细胞系生长的抑制作用
Cancer Res. 1996 Aug 1;56(15):3499-507.
8
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.一项针对晚期癌症患者的I期试验，以持续静脉输注方式给予c-Raf激酶反义寡核苷酸ISIS 5132。
Clin Cancer Res. 2000 May;6(5):1626-31.
9
Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.反义寡核苷酸：靶点验证及全身递送治疗性纳米颗粒的研发
Methods Mol Biol. 2007;361:163-85. doi: 10.1385/1-59745-208-4:163.
10
Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
Semin Oncol. 2003 Apr;30(2 Suppl 3):30-3. doi: 10.1053/sonc.2003.37273.

引用本文的文献

1
Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors.作为基因治疗传递和疫苗载体的结构 DNA 组装体的临床转化的机遇与挑战。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jan;13(1):e1657. doi: 10.1002/wnan.1657. Epub 2020 Jul 15.
2
Smart-Responsive Nucleic Acid Nanoparticles (NANPs) with the Potential to Modulate Immune Behavior.具有调节免疫行为潜力的智能响应性核酸纳米颗粒（NANPs）。
Nanomaterials (Basel). 2019 Apr 12;9(4):611. doi: 10.3390/nano9040611.
3
Chemical Modification of CRISPR Eliminate type I Interferon Responses in Human Peripheral Blood Mononuclear Cells.
CRISPR的化学修饰消除人外周血单个核细胞中的I型干扰素反应。
J Cytokine Biol. 2018;3(1). doi: 10.4172/2576-3881.1000121. Epub 2018 Jan 29.
4
Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles.利用RNA-RNA、RNA-DNA和DNA-RNA纳米颗粒触发RNA干扰。
ACS Nano. 2015 Jan 27;9(1):251-9. doi: 10.1021/nn504508s. Epub 2014 Dec 18.
5
Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.包裹2'-O-甲基化miR-34a的转铁蛋白共轭脂质纳米粒用于治疗多发性骨髓瘤。
Biomed Res Int. 2014;2014:217365. doi: 10.1155/2014/217365. Epub 2014 Feb 13.
6
The preparation of new phosphorus-centered functional groups for modified oligonucleotides and other natural phosphates.用于修饰寡核苷酸和其他天然磷酸盐的新型含磷官能团的制备。
Molecules. 2005 Sep 30;10(9):1048-73. doi: 10.3390/10091048.
7
CHARMM force field parameters for simulation of reactive intermediates in native and thio-substituted ribozymes.用于模拟天然及硫代取代核酶中反应中间体的CHARMM力场参数。
J Comput Chem. 2007 Jan 30;28(2):495-507. doi: 10.1002/jcc.20474.
8
Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.表皮生长因子诱导的p21（WAF-1/CIP-1）基因在MDA-MB-468人乳腺癌异种移植瘤中的反义成像
Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1273-80. doi: 10.1007/s00259-003-1134-0. Epub 2003 Mar 15.
9
Oligonucleotide directed misfolding of RNA inhibits Candida albicans group I intron splicing.寡核苷酸介导的RNA错折叠抑制白色念珠菌I组内含子剪接。
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11091-6. doi: 10.1073/pnas.172391199. Epub 2002 Aug 8.
10
Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucleotides targeted in vivo to hepatic endothelial cells.脂质包被的寡核苷酸阳离子脂质体在体内大量且选择性地递送至肝内皮细胞。
Pharm Res. 2002 May;19(5):676-80. doi: 10.1023/a:1015318415705.